British Journal of Haematology · 2020 · 11 citations · 9 references
MedicinePharmacologyPharmacotherapyHematologic OncologyImmunotherapyMedical OncologyCancer ImmunotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyMultiple MyelomaRelapsed DiseaseBortezomib TherapyBortezomib-based RegimensMultiple Myeloma TherapyMultiple Myeloma TreatmentRefractory Multiple MyelomaRelapsed Multiple Myeloma
The treatment of relapsed multiple myeloma (MM) is challenging due to increasing disease refractoriness, declining patient performance status and increasing patient co-morbidity.1 The combination of panobinostat, bortezomib and dexamethasone (PAN-Vd) is approved for the treatment of patients with relapsed MM based on the PANORAMA1 trial which compared PAN-Vd to placebo-Vd in patients with relapsed MM who were not previously refractory to bortezomib.2, 3 Subgroup analysis showed that the benefit from PAN-Vd was greatest in patients who had received ≥2 prior regimens including bortezomib and an immunomodulatory drug (IMiD) where the progression-free survival (PFS) was 12·5 months in the panobinostat arm versus 4·7 months in the placebo arm.3 The PANORAMA2 trial evaluated PAN-Vd in 55 heavily pretreated patients with bortezomib-refractory MM and the overall response rate (ORR) was 34·5% with a median PFS of 5·4 months.4 There is little published experience in such heavily pre-treated patients and in UK clinical practice this regimen is often positioned as 5th+ line therapy. In addition, there are no reports relating to a weekly bortezomib schedule. Therefore, we evaluated the efficacy and tolerability of PAN-Vd administered using a weekly bortezomib schedule in the setting of two tertiary MM centres. We conducted a retrospective case review of all patients commenced on PAN-Vd at the Royal Marsden Hospital (RMH) (April 2016–March 2019) and University College London Hospital (UCLH) (April 2016–January 2018) with follow-up until December 2019. Bortezomib was given at 1.3 mg/m2 weekly on D1, 8, 15, 22; panobinostat 20 mg on D1, 3, 5, 15, 17, 19; and dexamethasone 20–40 mg on D1, 8, 15, 22 of a 28-day cycle. A subset of patients had thalidomide 50–100 mg added. Treatment was delivered to a maximum of 16 cycles. Baseline demographics of patients were collected including cytogenetic risk which was assessed based on the most recent bone-marrow sample analysed by fluorescence in situ hybridisation (FISH). Cytogenetic high risk (HiR) was defined as the presence of any one of t(4;14), t(14;16), t(14;20), del(17p) and/or gain(1q). Toxicities during treatment were evaluated as per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.5 Response to treatment was assessed by International Myeloma Working Group criteria.6 Data were analysed using GraphPad Prism version 8 (GraphPad Software, San Diego, CA, USA), with median PFS and OS estimated using the Kaplan–Meier method and comparisons between subgroups using the log-rank test. In all, 75 patients received PAN-Vd (45 RMH, 30 UCLH). The median age of patients was 67 (range 36–85) and 60% of patients were male. All patients had previously been treated with a proteasome inhibitor (PI) and an IMiD and had received a median of four previous lines of therapy (range 2–8). Of the patients,51% were PI refractory, 63% were ISS stage 3 and 77% had HiR disease. Overall response rate (ORR) was 47% and minimal (MR) or better response rate was 60% (Table I). The median PFS was 3·5 months and median OS was 10 months (Fig 1A, B). Achievement of partial response (PR) or better was associated with longer PFS and OS (median PFS 6·2 months vs. 1·5 months, P < 0·001; OS 13 months vs. 5·4 months, P = 0·007; Fig 1C, D). The presence of HiR disease showed a trend towards shorter PFS and OS which did not reach statistical significance (median PFS 2·5 months vs. 5·4 months, P = 0·098; OS 9·3 months vs. 18 months, P = 0·151; Fig 1E, F). Patients who were previously refractory to PI therapy had a significantly shorter PFS and OS than those not previously refractory (median PFS 1·5 months vs. 5·3 months, P = 0·008; OS 7·6 months vs. 12·6 months, P = 0·040; Fig 1G, H). Patients who were initiated on thalidomide in addition to PAN- Vd (PAN-VTd) had a significantly shorter PFS and OS than those who were not (median PFS 1·1 months vs. 4·6 months, P = 0·004; OS 2·3 months vs. 11·3 months, P < 0·001; Fig 1I, J). Maximum response Whole cohort n = 75 n (%) PI refractory n = 38 n (%) HiR disease n = 34 n (%) Number of cycles received and toxicity data were collected for the 45 patients treated at RMH. Patients received a median of four (range 0·5–16) cycles of therapy. Among patients, 22% received less than two cycles, 24% received eight or more cycles and 7% received the maximum of 16 cycles. In all, 44 patients stopped therapy during the data collection period; 27% due to toxicity, 57% due to disease progression, 30% due to death and 5% due to maximum response achieved (categories are not mutually exclusive). The cause of death whilst on treatment was progressive disease in seven patients and adverse events in six patients (four infection, one cardiac failure and one intracerebral haemorrhage). The most common adverse events were haematological. Baseline cytopenias were common prior to commencing PAN-Vd therapy; 27% had baseline grade 3–4 anaemia, 7% grade 3–4 neutropenia and 33% grade 3–4 thrombocytopenia. Grade 3–4 cytopenias increased on therapy to anaemia 64%, neutropenia 42% and thrombocytopenia 76%. Transfusion of platelets and/or red cells was needed in 84% of patients. Dose reduction of bortezomib was recorded in 47%, of panobinostat in 71% and of dexamethasone in 40%. The 12 cases in which an adverse event was a documented reason for stopping PAN-Vd therapy included five peripheral neuropathy, two postural hypotension, two severe thrombocytopenia, two diarrhoea and one hyponatraemia and seizures. In this large real-world cohort of patients treated with PAN-Vd at median 5th-line therapy, the ORR was high at 47%. Median PFS was limited at 3·5 months with most patients stopping therapy due to disease progression. However, 27% stopped therapy due to adverse events suggesting that this regimen was difficult to deliver to some patients. Neuropathy, thrombocytopenia and diarrhoea were the main limiting toxicities with transfusion support required in most patients. Importantly, patients who achieved ≥PR had significantly longer survival than those who did not. A subset of patients was able to benefit from long term treatment. Our data showed a significantly longer PFS and OS for patients not previously refractory to PI therapy. However, 36% of patients who completed ≥8 cycles were previously PI refractory, suggesting patients in this group can still gain a durable benefit. The presence of HiR disease compared to non-HiR disease showed a trend towards shorter PFS and OS but this did not reach significance, which could reflect low numbers of patients in this analysis. Patients who were initiated on PAN-VTd had a reduced PFS and OS compared to those commenced on PAN-Vd. PAN-VTd has previously been shown to be an efficacious regime in patients who have received a median of one prior line of therapy.7 The number of patients in our PAN-VTd subgroup was low making it difficult to draw firm conclusions. Although it is possible that such heavily pre-treated patients were unable to tolerate quadruplet therapy, when we examined cause of death in this subgroup, adverse events only accounted for 14% of deaths with the majority being recorded as due to myeloma progression. Quadruplet therapy was often directed to patients with more aggressive disease features. Overall, our results are inferior to those of the PANORAMA1 study but our patient population is very different; when considering lines of therapy, PI-refractory status and cytopenias, it is likely that only 9% of our patients would have been eligible for PANORAMA1. Our results are more comparable to trials of heavily pre-treated patients such as the NIMBUS study (a median of five prior lines) in which the PFS with pomalidomide and dexamethasone was 4·0 months vs. 1·9 months with dexamethasone alone.8 Taken together these studies demonstrate the ongoing challenge of therapy in very heavily pre-treated disease. In summary, the combination of PAN-Vd can be effective for a subset of heavily pre-treated patients. Specific benefit is seen in patients who were not refractory to PIs, responding patients and possibly those with non-high-risk cytogenetics. These factors could be considered when discussing treatment options with patients. However, the regimen is associated with significant levels of haematological toxicity as well as important neurological and gastrointestinal side effects which need to be carefully monitored and actively managed in the outpatient setting, and were dose limiting in many patients. For future directions, our results suggest that there may be value in investigating attenuated dosing schedules when panobinostat is combined with bortezomib in the multiply relapsed setting. In addition, there is renewed interest in the combination of panobinostat with other novel agents. This treatment has been shown to upregulate CD38 expression and thereby may synergise with anti-CD38-directed therapy.9 It has also been trialled with lenalidomide-based regimens where it may have a more favourable side-effect profile.10, 11 SB, CP, NR and KB designed the study; SB, SN and PS collected the data; SB, CP, MK, NB and KB analysed and interpreted the data; SB, CP and KB drafted the manuscript. All authors contributed to critically revising the manuscript and approved the final submitted version.
9
Jesús F. San Miguel, Katja Weisel, Philippe Moreau et al. · The Lancet Oncology · 2013 · 799 citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 788 citations
Multiple myeloma: patient outcomes in real‐world practice
Kwee Yong, Michel Delforge, Christoph Driessen et al. · British Journal of Haematology · 2016 · 321 citations · Full text